Agilent

Agilent to 'turn back time' on preserved tumour samples

Agilent has licensed Kreatech's non-enzymatic labelling technology to allow researchers to study preserved tumour samples that would otherwise be too degraded to study on its microarray platform. The licensing of Kreatech Biotechnology's labelling technology will allow Agilent to optimise its comparative genomic hybridization (aCGH) microarray platform to study formalin-fixed paraffin-embedded (FFPE) tissue samples. aCGH is a method for analysing the number of mutations (copy number variations) in one DNA sample compared with another and can be used to identify the mutations involved with genetic diseases such as cancer.